0 Against all odds: anti-IgE for intrinsic asthma?

Thorax doi:10.1136/thoraxjnl-2013-203738

• Chest clinic

• Opinion

Against all odds: anti-IgE for intrinsic asthma?

1. 
   Marek Lommatzsch1, 


2. 
   Stephanie Korn2, 


3. 
   Roland Buhl2, 


4. 
   Johann Christian Virchow1
   

+Author Affiliations

1. 
   
   
   ¹Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany
   
   


2. 
   
   
   ²Pulmonary Department, Mainz University Hospital, Mainz, Germany
   
   

1. 
   Correspondence toDr Marek Lommatzsch, Abteilung für Pneumologie und Internistische Intensivmedizin, Zentrum für Innere Medizin, Universität Rostock, Ernst-Heydemann-Str. 6, Rostock 18057, Germany;marek.lommatzsch@med.uni-rostock.de
   

• 
  Received 14 April 2013


• 
  Revised 19 April 2013


• 
  Accepted 26 April 2013


• 
  Published Online First 24 May 2013

Abstract

For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma. In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.

This Article

1. Abstract


2. Full text


3. PDF